KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) Enterprise Value (2016 - 2025)

Acadia Pharmaceuticals has reported Enterprise Value over the past 16 years, most recently at -$819.7 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$819.7 million for Q4 2025, down 8.43% from a year ago — trailing twelve months through Dec 2025 was -$819.7 million (down 8.43% YoY), and the annual figure for FY2025 was -$819.7 million, down 8.43%.
  • Enterprise Value for Q4 2025 was -$819.7 million at Acadia Pharmaceuticals, up from -$847.0 million in the prior quarter.
  • Over the last five years, Enterprise Value for ACAD hit a ceiling of -$345.9 million in Q3 2023 and a floor of -$847.0 million in Q3 2025.
  • Median Enterprise Value over the past 5 years was -$510.8 million (2021), compared with a mean of -$544.9 million.
  • Biggest five-year swings in Enterprise Value: increased 22.81% in 2022 and later crashed 72.26% in 2024.
  • Acadia Pharmaceuticals' Enterprise Value stood at -$520.7 million in 2021, then rose by 19.95% to -$416.8 million in 2022, then fell by 5.29% to -$438.9 million in 2023, then plummeted by 72.26% to -$756.0 million in 2024, then decreased by 8.43% to -$819.7 million in 2025.
  • The last three reported values for Enterprise Value were -$819.7 million (Q4 2025), -$847.0 million (Q3 2025), and -$762.0 million (Q2 2025) per Business Quant data.